Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Deanna Jannat-Khah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Immune Checkpoint Inhibitors, Glucocorticoids, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NIAMS NIH HHS, Hospital for Special Surgery, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
Glucocorticoids are commonly used for rheumatoid arthritis (RA) treatment and to palliate some malignancies, but it is unclear whether glucocorticoids attenuate the benefits of immune checkpoint inhibitor (ICI) cancer therapy. We examined the association between glucocorticoid use and survival among ICI‐treated patients with RA and metastatic nonsmall cell lung cancer (mNSCLC).
Methods
A cohort of patients with RA enrolled in Medicare were identified based on the following: age ≥66 years, RA diagnosed before mNSCLC, and having initiated nivolumab, pembrolizumab, or atezolizumab (2015–2019, when approved only for mNSCLC). Landmark Kaplan‐Meier curves and time‐varying adjusted Cox models were used to examine the association between early glucocorticoid use (within 91 days after ICI initiation) and survival. Dexamethasone users were excluded from the primary analysis and included in a sensitivity analysis.
Results
We identified 663 ICI‐treated patients with RA and mNSCLC, with a mean age of 75 years, 86.9% being White, 64.7% being female, and 363 (46%) receiving glucocorticoids. Among users, the median average prednisone equivalents was 6.59 mg/d (interquartile range 3.30, 12.31). In a time‐varying Cox model, glucocorticoid use was not associated with survival. Additionally, in a 91‐day landmark model, glucocorticoid dose was not associated with survival (hazard ratio 1.01; 95% confidence interval 0.93, 1.10).
Conclusion
Glucocorticoids, at the dosages used to treat ICI‐treated patients with RA and mNSCLC, had a negligible effect on survival in the 91 days after ICI initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York.
- Department of Medicine, Division of Rheumatology, Weill Cornell Medicine, New York, New York.
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham.
- Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama.
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
ORCID-Profile: Deanna Jannat-Khah, Jeffrey R Curtis, Anne R Bass
Förderung
- NIAMS NIH HHS
- Hospital for Special Surgery
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Jannat-Khah, D., Curtis, J. R., Xie, F., Saxena, A., & Bass, A. R. (2026). Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?. Arthritis & Rheumatology. https://doi.org/10.1002/art.43445
Vancouver
Jannat-Khah D, Curtis JR, Xie F, Saxena A, Bass AR. Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?. Arthritis & Rheumatology. 2026. doi:10.1002/art.43445
BibTeX
@article{JannatKhah2026,
author = {Jannat-Khah, Deanna and Curtis, Jeffrey R and Xie, Fenglong and Saxena, Ashish and Bass, Anne R},
title = {Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43445}
}
EUVIMED